Publications & Presentationsbreadcrumb separatorPublicationsbreadcrumb separatorClinicalbreadcrumb separator2017
Clinical Publications 2017

1 One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. D.N. Podlekareva, A. Schultze, A. Panteleev, A.M. Skrahina, J.M. Miro,  A. Rakhmanova, H. Furrer, R.F Miller, A.M. W. Efsen, M.H. Losso, J. Toibaro, A. Vassilenko, E. Girardi, J.D. Lundgren, A. Mocroft, F.A. Post, O. Kirk, on behalf of the TB:HIV study group in EuroCoord.
AIDS. 2017;31(3):375-384. abstract

2 Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Annals of Internal Medicine. 2017;166(1):9-17. abstract

3 Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.  Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. 
HIV Medicine. 2017;18(1):33-44. abstract

4 Combination antiretroviral therapy and cancer risk. AH Borges
Current Opinion in HIV & AIDS. 2017;12(1):12-19. Abstract

5 Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. J O'Connor, MJ Vjecha, AN Phillips, B Angus, D Cooper, B Grinsztejn, G Lopardo, S Das, R Wood, A Wilkin, H Klinker, P Kantipong, KL Klingman, D Jilich, E Herieka, E Denning, I Abubakar, F Gordin, JD Lundgren; INSIGHT START study group.
Lancet HIV. 2017. pii: S2352-3018(16)30216-8. Abstract

6 Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, A Pikis, RR Razonable, V Miller, PD Griffiths; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum.
Clinical Infectious Diseases. 20171;64(1):87-91.Abstract

7 An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. 
F Nakagawa, V Delpech, J Albert, A Alioum, D Bezemer, M Cortina-Borja, AE Brown, V Cambiano, C Campbell, D Costagliola, A de Luca, R Kouyos, R Lodwick, JD Lundgren, N Pantazis, C Smith, V Supervie, P Tookey, G Touloumi, Zh Yin, A van Sighem, AN Phillips
AIDS. 2017;31(3):417-425. Abstract

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. M Casadellà; A Cozzi-Lepri; A Phillips; M Noguera-Julian; M Bickel; D Sedlacek; K Zilmer; B Clotet; JD Lundgren; R Paredes, on behalf of EuroSIDA in EuroCoord.
PLoS One. 2017;12(1):e0166613. abstract

9 Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? Peters L, Cozzi-Lepri A; Hepatitis C Working Group for the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord.
AIDS. 2017;31(5):661-668.  abstract

10 Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. 
HIV Med. 2017;18(3):171-180. abstract

11 Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AR Lifson, B Grund, EM Gardner, R Kaplan, E Denning, N Engen, CL Carey, F Chen, S Dao, E Florence, J Sanz, S Emery; INSIGHT START Study Group.
AIDS. 2017;31(7):953-963. abstract

12 Late presentation of chronic viral hepatitis for medical care: a consensus definition. S Mauss, S Pol, M Buti , E Duffell, C Gore, JV Lazarus ,HL  der Grient, J Lundgren, A Mozalevskis, D Raben, E Schatz, S Wiktor, JK Rockstroh; European consensus working group on late presentation for Viral Hepatitis Care.
BMC Medicine 2017; 15(1):92 abstract

13 Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholc L, Kyselyova G, Lungren JD, Mocroft A; for EuroSIDA.
Clin Infect Dis. 2017;64(10):1413-1421. abstract

14 Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner,  D Duprez, S Emery, B Gazzard, J Gordin, G Grandits, AN Phillips, S Schwarze, EZ Soliman, SA Spector, G Tambussi, J Lundgren; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.
Journal of the American Heart Association 2017; 6(5). Abstract 

15 Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. TS Itenov, JU Jensen, SR Ostrowski, PI Johansson, KM Thormar, JD Lundgren, MH Bestle; “Procalcitonin And Survival Study” study group.
Shock 2017, 47(6) 696-701. Abstract

16 Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. JD Kowalska, C Oprea, S de Witt, A Pozniak, D Gökengin, M Youle,JD Lundgren, A Horban; ECEE Network Group.
HIV Medicine 2017, 18(5): 370-375. Abstract

17 Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. E Lord, AJ Stockdale, R Malek, C Rae, I Sperle, D Raben, A Freedman, D Churchill, J Lundgren, AK Sullivan; British Association of Sexual Health HIV (BASHH)/British HIV Association (BHIVA) guideline review group for the Optimising Testing and Linkage to Care for HIV across Europe (OptTEST) project by HIV in Europeb.
HIV Medicine 2017; 18(4): 300-304. Abstract

18 Hepatitis C virus (HCV) RNA profiles among chronic HIV/HCV-coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in nine individuals. D Grint, E Tedaldi, L Peters, A Mocroft, B Edlin,S Gallien, H Klinker, C Boesecke, P Kokordelis, JK Rockstroh.
HIV Medicine 2017, 18(6):430-434. Abstract

19 Small airway dysfunction in well-treated never-smoking HIV-infected individuals. A Ronit, IH Mathiesen, M Gelpi, T Benfield, J Gerstoft , T Pressler, A Christiansen, J Lundgren, J Vestbo, S Dam Nielsen.
European Respiratory Journal 2017; 2;49(3). Abstract

20 The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. NE Wareham, JD Lundgren, C Da Cunha-Bang, F Gustafsson, M Iversen, HH Johannesen, A Kjær, A Rasmussen, H Sengeløv, SS Sørensen, BM Fischer.
European Journal of Nuclear Medicine and Molecular Imaging 2017;44(3):421-431. Abstract

21 The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.
AIDS. 2016;30(17):2659-2663. Abstract

Predictors of eGFR Progression, Stabilisation or Improvement After Chronic Renal Impairment in HIV-positive individuals. L Ryom, A MOcroft, O Kirk, M Ross, C Smith, O Moranne, P Morlat, CA FUX; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group.
AIDS. 2017. abstract


1 Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. G Chêne,A Phillips, D Costagliola, JA Sterne, H Furrer, J Del Amo, A Mocroft, A d'Arminio Monforte, F Dabis, JM Miro, D Barger, M Termote, C Schwimmer, R Salbøl Brandt, N Friis-Moller, D Raben, D Haerry, M Egger, I Weller, S De Wit.
International Journal of Epidemiology. 2016 . Abstract

2 The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. A Schultze ,R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, M Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri.
Antivir Ther. 2017  [Epub ahead of print]  Abstract 

3 Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. JF Hoy, B Grund, M Roediger, AV Schwartz, J Shepherd, A Avihingsanon, S Badal-Faesen, S de Wit, S Jacoby , A La Rosa, S Pujari, M Schechter, D White, NW Engen, K Ensrud, PD Aagaard, Carr A14; INSIGHT START Bone Mineral Density Substudy Group.
Journal of Bone and Mineral Research 2017.  [Epub ahead of print] Abstract

4 Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based cART regimens. A Cozzi-Lepri, R Zangerle, L Machala, K Zilmer, M Ristola, C Pradier, O Kirk, J Grarup, Helen Sambatakou, Gerd Fätkenheuer, Israel Yust, Patrick Schmid, Magnus Gottfredsson, Irina Khromova, David Jilich , Robert Flisiak, Jelena Smidt, Baiba Rozentale, Roxana Radoi, Marcelo H Losso, JD Lundgren, A Mocroft1 on behalf of EuroSIDA.
HIV Medicine 2017

5 Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable?C Ekenberg, IP Lodding, NE Wareham, SS Sørensen, H Sengeløv, F Gustafsson, A Rasmussen, M Perch, JD Lundgren, M Helleberg
Eur J Clin Microbiol Infect Dis. 2017. [Epub ahead of print] Abstract

6  Are we successfully managing cardiovascular disease in people living with HIV? CI Hatleberg, JD Lundgren, L Ryom.
Curr Opin HIV AIDS. 2017. Abstract